Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials
Related News

Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
First Posted Date
2009-08-21
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
907
Registration Number
NCT00963599

Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: montelukast sodium
First Posted Date
2009-08-21
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
1079
Registration Number
NCT00963469

A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: montelukast sodium
First Posted Date
2009-08-17
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
829
Registration Number
NCT00960141

Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)

First Posted Date
2009-08-06
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
77
Registration Number
NCT00953680

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Phase 1
Completed
Conditions
Pain
Interventions
Drug: etoricoxib
First Posted Date
2009-07-23
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
36
Registration Number
NCT00945035

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Phase 1
Completed
Conditions
Hypertension
Interventions
Drug: losartan potassium
First Posted Date
2009-07-22
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
13
Registration Number
NCT00943852

Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: montelukast sodium
First Posted Date
2009-07-22
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
190
Registration Number
NCT00943397

Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)

Not Applicable
Completed
Conditions
Asthma
Interventions
Drug: montelukast sodium
First Posted Date
2009-07-22
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
256
Registration Number
NCT00943683

Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)

Completed
Conditions
Anovulation
Interventions
Drug: Follitropin beta
First Posted Date
2009-06-15
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
384
Registration Number
NCT00920634

Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)

Completed
Conditions
Fertilization in Vitro
Interventions
Drug: Follitropin beta
First Posted Date
2009-06-15
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
1664
Registration Number
NCT00920361
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy